O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 8.65 GBX 1.76%
Market Cap: 34.9m GBX
Have any thoughts about
Ondine Biomedical Inc?
Write Note

Ondine Biomedical Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ondine Biomedical Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
O
Ondine Biomedical Inc
LSE:OBI
Cash from Operating Activities
-CA$13.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Cash from Operating Activities
-$5.8m
CAGR 3-Years
32%
CAGR 5-Years
38%
CAGR 10-Years
3%
Profound Medical Corp
TSX:PRN
Cash from Operating Activities
-$24.8m
CAGR 3-Years
0%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Cash from Operating Activities
-CA$14.5m
CAGR 3-Years
-144%
CAGR 5-Years
-69%
CAGR 10-Years
-46%
Theralase Technologies Inc
XTSX:TLT
Cash from Operating Activities
-CA$3.3m
CAGR 3-Years
1%
CAGR 5-Years
-3%
CAGR 10-Years
-2%
MedMira Inc
XTSX:MIR
Cash from Operating Activities
-CA$2.9m
CAGR 3-Years
-80%
CAGR 5-Years
-26%
CAGR 10-Years
5%
No Stocks Found

Ondine Biomedical Inc
Glance View

Market Cap
34.9m GBX
Industry
Health Care

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.

OBI Intrinsic Value
4.24 GBX
Overvaluation 51%
Intrinsic Value
Price
O

See Also

What is Ondine Biomedical Inc's Cash from Operating Activities?
Cash from Operating Activities
-13.7m CAD

Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Cash from Operating Activities amounts to -13.7m CAD.

What is Ondine Biomedical Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
16%

Over the last year, the Cash from Operating Activities growth was 16%.

Back to Top